The main items in the report are:
Highlights
Operating profit improved by NOK16.7 million to NOK-5.7 million (NOK-22.5 million)
Liquid funds amounted to NOK161.9 million at the end of the period.
Cevira – patient recruitment started in phase I/II study for photodynamic treatment of precancerous lesions of the cervix.
Lumacan – patient recruitment started in phase I/II study for photodynamic detection of colon cancer using an oral capsule as administration of the drug.
Photocure won a patent case extending the patent on Metvixia™ in the USA until July 2018.
President and chief executive officer of Photocure, Kjetil Hestdal MD, PhD, says in a comment to the results, “We are pleased to present another quarter with growth in sales of Hexvix and Metvix/Aktilite.
Photocure has now a positive contribution to the operating profit in the Nordic region, reflecting the previous investment in marketing and sales.”
